文献速递类风湿关节炎脊柱关节炎其他结缔组织病

风湿与肌肉骨骼疾病患者用药不良事件临床预测模型:系统文献综述

Clinical prediction models for medication adverse events in patients with rheumatic and musculoskeletal conditions: A systematic literature review.
PubMed 文献 · Semin Arthritis Rheum · 2025-04-11

该系统综述检索截至2024年3月的PubMed、Embase和Medline,纳入12项研究共17个预测风湿与肌肉骨骼疾病用药不良事件的临床预测模型。多数模型聚焦类风湿关节炎和改善病情抗风湿药,12个模型(70.5%)因变量选择不当和样本量问题存在高总体偏倚风险。

要点

  • 共纳入12项研究、17个临床预测模型,多数模型(76.4%)聚焦类风湿关节炎和改善病情抗风湿药。
  • 甲氨蝶呤相关模型占69.2%,生物制剂相关模型占15.3%。
  • 12个模型(70.5%)因变量选择方法不当和样本量问题存在高总体偏倚风险。

核心结论

  • 这是首个总结风湿与肌肉骨骼疾病用药不良事件临床预测模型的系统综述,现有模型存在方法学缺陷,包括变量选择不当和缺乏明确的样本量论证。
  • 未来模型可考虑覆盖更广泛的风湿与肌肉骨骼疾病和药物,并探索机器学习等能建模复杂交互作用的新方法以及预测同一类药物多种不良事件的多结局预测模型。

研究设计与样本

  • 系统文献综述,检索PubMed、Embase和Medline数据库截至2024年3月。
  • 纳入标准为开发多变量临床预测模型预测成人风湿与肌肉骨骼疾病用药不良事件的研究。
  • 从2406项研究中筛选1734篇标题/摘要,全文审阅38篇,最终12项研究报道的17个临床预测模型符合纳入标准。
  • 采用CHARMS清单提取数据、PROBAST清单评估偏倚风险。

主要发现

  • 17个临床预测模型中,76.4%聚焦类风湿关节炎和改善病情抗风湿药。
  • 甲氨蝶呤相关模型占69.2%,生物制剂相关模型占15.3%。
  • 常用Cox比例风险模型或逻辑回归模型。
  • 12个模型(70.5%)因变量选择方法不当和样本量问题存在高总体偏倚风险。

局限性

  • 现有临床预测模型存在方法学缺陷,包括变量选择方法不当和缺乏明确的样本量论证。
  • 12个模型(70.5%)存在高总体偏倚风险。
  • 作者指出未来模型可考虑覆盖更广泛的风湿与肌肉骨骼疾病和药物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This systematic review aims to identify, summarize, and evaluate the methodological quality of existing clinical prediction models (CPMs) that predict adverse events (AEs) associated with medications prescribed for rheumatic and musculoskeletal diseases (RMDs). METHODS: We searched PubMed, Embase, and Medline databases up to March 2024. Studies were included if they developed multivariable CPM predicting AEs in adult patients using RMD medications. Data extraction and quality assessment were conducted using the Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies (CHARMS) and Prediction model Risk Of Bias Assessment Tool (PROBAST) checklists to ensure consistent reporting and assess the risk of bias (ROB). RESULTS: Of 2406 studies identified, 1734 titles/abstracts were screened, and 38 were reviewed in full. Twelve studies reporting 17 CPMs met eligibility criteria. Most CPMs (76.4 %) focused on rheumatoid arthritis and disease modifying anti-rheumatic drugs (DMARDs) such as methotrexate (69.2 %) and biologic drugs (15.3 %). Cox proportional hazards or logistic regression models were commonly used. Twelve models (70.5 %) had high overall ROB due to inappropriate variable selection methods and sample size. CONCLUSIONS: This is the first systematic review summarising CPMs for AEs associated with RMD medications. It highlights that existing CPMs are affected by methodological pitfalls, including inappropriate variable selection and lack of clear sample size justification. Future models could consider a broader range of RMDs and medications. Emerging methods such as machine learning with the ability to model complex interactions, and multi-outcome CPMs to predict several AEs to one class of drug may improve predictions.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Diomatari C, Martin GP, Jenkins DA, et al. Clinical prediction models for medication adverse events in patients with rheumatic and musculoskeletal conditions: A systematic literature review. Semin Arthritis Rheum. 2025. PMID: 40262328. doi:10.1016/j.semarthrit.2025.152728

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。